- Home
- ZKH vs ATXS Comparison
ZKH vs ATXS Comparison
Compare ZKH & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZKH
- ATXS
- Stock Information
- Founded
- ZKH 1998
- ATXS 2008
- Country
- ZKH China
- ATXS United States
- Employees
- ZKH N/A
- ATXS N/A
- Industry
- ZKH
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ZKH
- ATXS Health Care
- Exchange
- ZKH Nasdaq
- ATXS Nasdaq
- Market Cap
- ZKH 616.9M
- ATXS 669.8M
- IPO Year
- ZKH 2023
- ATXS 2015
- Fundamental
- Price
- ZKH $3.83
- ATXS $9.37
- Analyst Decision
- ZKH Strong Buy
- ATXS Strong Buy
- Analyst Count
- ZKH 2
- ATXS 5
- Target Price
- ZKH $12.65
- ATXS $25.60
- AVG Volume (30 Days)
- ZKH 67.7K
- ATXS 219.2K
- Earning Date
- ZKH 11-22-2024
- ATXS 11-13-2024
- Dividend Yield
- ZKH N/A
- ATXS N/A
- EPS Growth
- ZKH N/A
- ATXS N/A
- EPS
- ZKH N/A
- ATXS N/A
- Revenue
- ZKH $1,213,635,386.00
- ATXS N/A
- Revenue This Year
- ZKH $4.02
- ATXS N/A
- Revenue Next Year
- ZKH $16.24
- ATXS N/A
- P/E Ratio
- ZKH N/A
- ATXS N/A
- Revenue Growth
- ZKH 2.49
- ATXS N/A
- 52 Week Low
- ZKH $2.62
- ATXS $4.26
- 52 Week High
- ZKH $21.91
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- ZKH 54.01
- ATXS 30.44
- Support Level
- ZKH $3.75
- ATXS $11.40
- Resistance Level
- ZKH $4.03
- ATXS $11.75
- Average True Range (ATR)
- ZKH 0.23
- ATXS 0.75
- MACD
- ZKH -0.01
- ATXS -0.23
- Stochastic Oscillator
- ZKH 50.51
- ATXS 7.64
About ZKH ZKH Group Limited each representing thirty-five (35)
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.